Home › Foot Injuries and Disorders › NCT06780202

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

Who can join

Ages 18 to 95 · All sexes

Inclusion Criteria:

-Emory Orthopedic patients undergoing foot and ankle surgery

Exclusion Criteria:

* Concurrent or significant injuries to other bones or organs
* Local infections
* History of alcohol or medical abuse, including prior opioid abuse
* Smoking
* History of severe heart disease, renal failure, liver dysfunction, active peptic ulcer disease, diabetes, rheumatoid arthritis, neurological or psychiatric diseases that could influence pain perception
* Pre-existing immune suppression
* Those deemed possibly non-compliant by the study team and,
* All vulnerable populations (those unable to give consent, juveniles, pregnant women, prisoners, cognitively impaired and non-English speaking).

About the study

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.

The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

What is being tested

• medrol dosepak (drug)
• HYDROcodone Oral Tablet (drug)

Sponsor: Emory University · Participants: 180 · Started: Jan 27, 2025

Contact the study team

• Jason Bariteau, MD · Phone: 404-778-3350

Official record on ClinicalTrials.gov — NCT06780202

Locations in the U.S.

Conditions

• Foot Injuries and Disorders
• Ankle Injuries and Disorders

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.